Hansa Biopharma: Improved sales and pipeline activity at a higher cost - Redeye

Hansa delivers positive sales in Q2 and SEK 30m of product sales is the highest lever within a year. Hansa's pipeline prospects are also improving significantly. The flip side is a negative OPEX surprise. Initially we expect a slight positive reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/923953/hansa-biopharma-improved-sales-and-pipeline-activity-at-a-higher-cost?utm_source=finwire&utm_medium=RSS